With many new agents designed to treat PsA, rheumatologists and patients have options. Schwartzman et al. examined the real-world use of different treatments and ranked patient medication preferences.
Search results for: hospital
Denosumab vs. Zoledronate: An Analysis of Treatments for Low Bone Mineral Density in Patients with HIV
In a small study of men with low bone mineral density (BDM) living with HIV and taking anti-retroviral therapy, both zoledronate or denosumab were well tolerated and effective for bone mineral density of the lumbar spine and femoral neck.
Risk of Adverse Outcomes Due to COVID-19 May Be Lower with TNF Inhibitor Monotherapy
Findings support the continued use of TNF inhibitor monotherapy in individuals with immune-mediated inflammatory diseases. In the study, these patients had a lower risk of hospitalization or death caused by COVID-19 than patients on other commonly prescribed treatment regimens
Anifrolumab Promising for Sustained Low Disease Activity in Patients with Lupus
ACR CONVERGENCE 2021—Using pooled data from the TULIP-1 and TULIP-2 clinical trials, researchers set out to identify whether more patients with systemic lupus erythematosus (SLE) being treated with anifrolumab achieved a low disease activity state than patients with SLE who received placebo.1-3 An analysis of the data was presented at ACR Convergence 2021 by Eric…
Outcomes in Patients with Rheumatic Diseases & COVID-19
Background & objectives: Patients with rheumatic and musculoskeletal diseases (RMDs) may be at an increased risk of SARS-CO-V2 infection as a result of underlying disease, associated comorbidities and use of potentially immunosuppressive treatments. Further, concern exists regarding whether individuals with rheumatic diseases potentially experience more severe COVID-19 and poorer outcomes. This study was undertaken to…
Beating the Workforce Shortage: 4 Practices Share Best Practices in ACR Town Hall
At a recent ACR town hall, four rheumatologists shared strategies that have helped them recruit new physicians amid a significant nationwide rheumatology workforce shortage.
Pre-Eclampsia Risk & Rheumatic Disease
Secher et al. evaluated the risk of pre-eclampsia in pregnant patients with RA, axSpA or PsA, assessing the effect of disease activity and disease-modifying anti-rheumatic drugs on this risk.
2 New Clinical Practice Guidelines for JIA Released
Two new ACR Clinical Practice Guidelines provide recommendations on the pharmacologic management of JIA, focusing on treatment of oligoarthritis, temporomandibular arthritis & systemic JIA, as well as nonpharmacologic therapies, medication monitoring, immunizations & imaging.
ARCTIC Rewind: Effects of Half Dose of csDMARDs in Patients with RA in Remission
A study examined the effect of reducing the dose of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) by half in patients with RA in remission, finding the change increased the incidence of flare in 25% of patients.
FDA Approves Risankizumab-rzaa for PsA
Two recent trials demonstrated the safety and efficacy of risankizumab-rzaa for the treatment of adults with active psoriatic arthritis.
- « Previous Page
- 1
- …
- 46
- 47
- 48
- 49
- 50
- …
- 319
- Next Page »